Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial investigates the safety and potential efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) for moderate to severe active Systemic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Metabolically Armed CD19 CAR-T Cells (Meta10-19)

Snippet

Sponsor: Zhejiang University | Conditions: Systemic Lupus Erythematosus | EARLY_Phase 1 | Status: RECRUITING